Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone716-849-6810
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.14 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions
What is Cleveland BioLabs' stock symbol?
Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."
How were Cleveland BioLabs' earnings last quarter?
Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.05) earnings per share for the quarter. The biotechnology company earned $0.28 million during the quarter. Cleveland BioLabs had a negative net margin of 304.43% and a negative return on equity of 96.01%. View Cleveland BioLabs' Earnings History.
When is Cleveland BioLabs' next earnings date?
Has Cleveland BioLabs been receiving favorable news coverage?
News coverage about CBLI stock has been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cleveland BioLabs earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Cleveland BioLabs.
Are investors shorting Cleveland BioLabs?
Cleveland BioLabs saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 27,400 shares, an increase of 25.1% from the August 30th total of 21,900 shares. Based on an average daily trading volume, of 9,000 shares, the days-to-cover ratio is presently 3.0 days. Currently, 0.6% of the shares of the company are sold short. View Cleveland BioLabs' Current Options Chain.
Who are some of Cleveland BioLabs' key competitors?
What other stocks do shareholders of Cleveland BioLabs own?
Who are Cleveland BioLabs' key executives?
Cleveland BioLabs' management team includes the folowing people:
- Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)
- Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)
- Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)
- Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
- Dr. Andrei Purmal Ph.D., VP of Chemistry
How do I buy shares of Cleveland BioLabs?
Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cleveland BioLabs' stock price today?
One share of CBLI stock can currently be purchased for approximately $0.79.
How big of a company is Cleveland BioLabs?
What is Cleveland BioLabs' official website?
How can I contact Cleveland BioLabs?
Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]
MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
